SIC
KRYS icon

SJS Investment Consulting’s Krystal Biotech KRYS Stock Holding History

SJS Investment Consulting’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49K Hold
4
– – ﹤0.01% 1888
2026
Q1 		$1.03K Buy
4
+1
+33% +$266 ﹤0.01% 1457
2025
Q4 		$741 Buy
+3
New +$631 ﹤0.01% 1396
2022
Q4 		– Sell
-1
Closed – – 1655
2022
Q3 		$0 Buy
+1
New +$72 ﹤0.01% 1299

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SJS Investment Consulting's KRYS Position: Q2 2026 in Review

SJS Investment Consulting held its Krystal Biotech (KRYS) position steady in Q2 2026 at 4 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #1888.

SJS Investment Consulting first reported a position in KRYS in Q3 2022 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • SJS Investment Consulting held 4 shares of Krystal Biotech worth $1.49K as of Q2 2026.
  • SJS Investment Consulting left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1888 holding.
  • SJS Investment Consulting first reported a position in Krystal Biotech in Q3 2022 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.